This is the gap I think most investment memos miss. The memo tells you what the platform will do: six acquisitions over four years, two operating pa…

Read more

Sequencing often gets treated as an execution detail — something to optimise once targets are identified and capital is available. In practice, sequencing is the first place where a buy-and-build strategy meets reality, and where its assumptions begin to strain.

Why sequencing comes before scale

From the outside, buy-and-build appears additive: one deal follows another, revenue grows, headcount increases, the platform expands. From the inside, each acquisition changes the conditions under which the next one will occur. Leadership attention is reallocated, integration work consumes capacity, operating cadence shifts, and informal coordination mechanisms that once worked begin to fray.

Sequencing determines whether those changes build capability or consume it. This is why two platforms pursuing similar strategies can experience very different outcomes — the difference is often the order in which complexity is introduced rather than ambition, intelligence, or deal quality.

Early deals do disproportionate work

In buy-and-build systems, early acquisitions matter more than later ones. They establish how integration is approached, what “normal” disruption looks like, how much strain leaders are expected to carry, and whether learning is captured or lost. These early patterns become defaults, and later deals inherit them — often unquestioned.

If early acquisitions overwhelm the organisation, the lesson learned is usually “push through” rather than “slow down,” which over time produces fragility masked as momentum. When early sequencing respects capacity instead, the organisation develops muscles it can reuse: integration becomes more predictable, decision-making improves, and optionality expands.

Sequencing in this sense is about setting the learning trajectory, not about speed.

Good deals at the wrong time

One of the harder judgments in buy-and-build is deferring a deal that looks attractive on paper. This is where sequencing becomes uncomfortable, especially in capital-rich environments. The question shifts from “is this a good company?” to “what will this do to the system we’re already carrying?”

Experienced operators recognise this tension intuitively. Deals get delayed not because of fit or valuation, but because leadership bandwidth is stretched, integrations are incomplete, or systems are mid-transition. These decisions rarely show up in post-mortems or case studies, but they often determine long-term outcomes.

A buy-and-build strategy that can’t say “not yet” is brittle, not aggressive.

Sequencing reveals the real constraint

Sequencing acts as a stress test because it exposes the true limiting factor in the system. The pattern repeats across the cases I’ve studied closely: when leadership attention collapses after the second or third acquisition, the constraint is leadership capacity rather than deal sourcing. When integrations pile up unresolved, the constraint is absorption capability rather than strategy. When decision quality deteriorates, the constraint is operating cadence rather than talent.

Sequencing surfaces those limits early — if leaders are willing to pay attention to them. Ignoring the signals doesn’t remove the constraint; it postpones the consequences.

Why sequencing is a strategic choice

Treating sequencing as strategic requires a shift in mindset. The question changes from “how many deals can we do this year?” to a narrower set:

• What capabilities must exist before the next deal?

• What needs to stabilise before complexity increases again?

• What did we actually learn from the last acquisition?

Those questions slow momentum and they improve resilience. They also explain why successful buy-and-build platforms often appear conservative early. The conservatism is investment in future optionality, not caution.

What comes next

Sequencing is the first stress test because it’s the earliest place where buy-and-build assumptions meet organisational limits. The next piece works on what sequencing exposes most clearly: integration capacity — how it accumulates, how it erodes, and why it ultimately determines whether buy-and-build compounds or collapses.

If buy-and-build is a system under load, sequencing is the moment you find out how strong the system really is.

In practice, buy-and-build is neither simple nor obvious, and the reason many strategies struggle has less to do with deal quality than with a misunderstanding of what buy-and-build actually is.

Buy-and-build is more than growth by acquisition

At first glance, buy-and-build looks like an alternative growth engine. Companies accelerate growth by acquiring businesses that already exist instead of expanding slowly through new products, customers, or geographies. The appeal is clear: faster scale, broader capabilities, and the potential to create value through integration.

Consulting frameworks explain the economic logic well, academic research has studied the conditions under which buy-and-build outperforms other strategies, and experienced investors and operators apply these ideas every day. All of that work matters. What it doesn’t always capture is how buy-and-build behaves once it moves from concept to operating reality.

From the inside, buy-and-build feels different

Inside an operating company, buy-and-build feels less like a growth plan being executed and more like an organisation gradually taking on weight. Each acquisition adds more than revenue or capability. It adds:

• integration work that competes with day-to-day operations,

• leadership attention that has to be redirected,

• cultural differences that require negotiation rather than resolution,

• systems strain that often appears months after close, and

• decisions about sequencing that cannot be undone.

None of these challenges arrive all at once — they accumulate quietly. This is why many buy-and-build efforts don’t fail dramatically. They slow down. Execution becomes uneven, decision-making turns reactive, and performance drifts before anyone can point to a single mistake.

The constraint is rarely capital

One of the most persistent misconceptions about buy-and-build is that capital is the primary constraint. In practice, capital is often available well before the organisation is ready to absorb what that capital enables. The real constraints tend to be organisational: leadership bandwidth, integration capability, operating cadence, and the ability to learn from one deal before moving to the next.

When those limits are exceeded, adding another acquisition increases fragility rather than accelerating growth. This dynamic explains why two platforms pursuing similar strategies can produce very different outcomes. The difference is capacity — not ambition or intelligence.

Why sequencing changes everything

This is where buy-and-build begins to behave less like a strategy and more like a system. Early acquisitions matter disproportionately. They establish integration norms, expectations about pace, how much disruption is tolerated, and whether experience compounds into capability or dissipates into noise. Later acquisitions inherit the system that earlier ones created.

From this perspective, sequencing is a strategic choice about how much complexity the organisation takes on, and when — not a technical detail. Practitioners often recognise this intuitively. Deals that look attractive on paper are sometimes deferred, not because they don’t fit, but because the organisation isn’t ready yet. The question becomes “what will this do to the system we’re already carrying?” rather than “is this a good company?”

Buy-and-build as a system under load

Viewed this way, buy-and-build is best understood as a system operating under increasing load. Each acquisition changes the conditions under which the next one will occur. Leadership attention shifts, integration capacity stretches, and optionality narrows or expands depending on how well complexity is absorbed.

This is why buy-and-build can’t be reduced to a checklist or a formula. Its outcomes emerge over time, shaped by interaction effects that are difficult to see at the outset. Understanding those interactions is the real strategic work.

What this section will explore

The purpose of this Buy & Build Strategy section is to examine these dynamics deliberately, complementing existing frameworks by staying with operating reality a bit longer — where strategy meets capacity, sequencing, and leadership constraints. Over time, the section will return to questions like:

• how platforms create or lose expandability,

• how adjacency and distance affect integration risk,

• why sequencing matters more than deal volume, and

• how learning either compounds or breaks down across acquisitions.

Many practitioners already manage buy-and-build with these considerations in mind. The aim here is to give that intuition clearer language and to explore where it holds, and where it begins to strain.

Buy-and-build is about building organisations that can survive the deals you choose to do, more than it’s about doing more deals.

Why I’m writing this

I’m documenting what I’ve learned as an operator and what I’m uncovering through doctoral research into buy-and-build strategy, target selection, sequencing, and integration. The work will evolve and get challenged over time, and all of it stays grounded in operating reality.

If you’re a PE operator, builder, founder, searcher, or investor thinking seriously about acquisitions, I hope these field notes help you see buy-and-build more clearly. This piece sets the foundation; the rest of The Industrialist builds on it.

— Dave

Most of the time, the deals don’t explain the difference. In the platforms I’ve followed long enough to see the divergence, the theses were sound, the targets were reasonable, and the diligence caught what it was meant to catch. What separated the two platforms was something the investment memos didn’t model: whether the organisation itself kept compounding capability as it absorbed more complexity, or whether it quietly lost capability each time the acquisition load went up.

That distinction is what this section is about. Most writing on buy-and-build focuses on transactions — sourcing, pricing, synergies, capital structure. Those elements matter; they also explain only part of why some platforms compound value over time while others slow down, fragment, or stall even when the deals themselves look similar.

This section treats buy-and-build differently: as a coordinating logic that governs how complexity is introduced, absorbed, and managed as the organisation grows, rather than as a set of acquisition tactics.

Buy-and-build as a system, not a sequence of deals

On the surface, buy-and-build looks linear: acquire a platform, execute add-ons, integrate, repeat. From an operating vantage point it isn’t linear at all. Each acquisition introduces new interfaces — between people, systems, processes, and decision rights — and those interfaces interact. Their effects compound. What initially feels like incremental growth becomes a change in how the organisation actually functions.

The central strategic question isn’t “can we execute the next acquisition?” It’s “what kind of system are we building as complexity accumulates?”

Sequencing as a design choice

In buy-and-build, order matters. Early acquisitions shape routines, expectations, and integration norms. Later acquisitions get absorbed into whatever system those earlier choices created — for better or worse.

That makes sequencing a design decision rather than a timing optimisation. Well-sequenced platforms let learning consolidate between acquisitions. Poorly sequenced platforms accumulate unresolved strain. Over time, the difference shows up as declining decision quality, slower execution, and more reliance on escalation — rarely as a single visible failure.

Integration capacity as the binding constraint

Financial models often assume integration is repeatable. Operating reality suggests otherwise. Integration draws on finite resources: leadership attention, decision clarity, organisational trust, and the ability to resolve ambiguity under pressure. These resources don’t scale automatically with deal volume.

As acquisitions accumulate, integration capacity often becomes the binding constraint — long before capital or opportunity does. Understanding buy-and-build therefore requires understanding where that constraint sits, how it shifts over time, and what happens when it is exceeded.

What this section examines

The essays in this section work through buy-and-build as a system under load: why platforms with similar deal strategies diverge over time, how sequencing shapes the organisation’s ability to absorb complexity, and why integration capacity rather than deal quality often determines outcomes. The focus is on the underlying logic that governs whether complexity compounds into capability or collapses into friction. (If you’re new here, How to Read This Project lays out the full structure and the recommended reading paths across sections.)

What the essays share is one question: what changes about the organisation as it grows through acquisition, and is that change something the system can sustain? That question is the central one for anyone running, funding, or advising a buy-and-build platform — and it governs most of what follows from here.